67915-31-5
67915-31-5 结构式
基本信息
曲康唑
特康唑
TERCONAZOLE
Terconagole
TERCONAZOLE EPT(CRM STANDARD)
TERCONAZOLE USP(CRM STANDARD)
Triaconazole
1-[4-[[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-yl-piperazine
Fungistat
Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, cis
物理化学性质
安全数据
常见问题列表
曲康唑对念珠菌、许表皮癣菌和其他真菌有抗菌作用对某些细菌也有抗菌作用；主要用于外阴阴道念珠菌病的治疗。
对0.4%曲康唑和2%咪康唑膏的不良反应进行研究，曲康唑组皮疹、生殖道刺激、疼痛和妁热的发生率分别为1.3%、3.1%、1.2%和5.2%；咪康唑组生殖道刺激、疼痛和妁热的发生率分别为0.9%、3.1%、10.5%，咪康唑组患者未出现皮疹，有2%患者出现流涕(rhinorrhea)。比较曲康唑阴道栓80mg和咪康唑栓的不良反应情况，分别有6.3%的曲康唑组患者和0.7%咪康唑组患者用药后出现腹痛，两组患者的其他不良反应发生率相似。Hyder等(1994)报道应用曲康唑治疗VVC后患者出现发热和白细胞升高。
Terconazole inhibits the growth of Candida albicans ATCC 44859 in a concentration-related manner, but with modest effects noted at levels from 0.1 to 10 μM when the yeast is grown on media favoring the cell form. The inhibitory potency of terconazole on yeast cell viability varies with the strain and species of Candida tested. The susceptibility of C. albicans ATCC 44859 to terconazole is markedly enhanced when the yeast is grown on Eagle minimum essential medium, which favors mycelium formation. There is a progression of changes, from loss of mycelia formation at 0.1 μM terconazole through complete necrosis at 100 μM. Terconazole blocks the morphogenetic transformation from the yeast into the filamentous form at concentrations of 0.008 to 0.05 microgram/mL.
A 3-day once-daily intravaginal application of terconazole 0.8% is usually sufficient to provide a functional therapeutic period of 7 days because of prolonged high biologically active antifungal levels in the vagina. No side effects are observed at any concentration of terconazole.